DrugPatentWatch Database Preview
TRELEGY ELLIPTA Drug Profile
When do Trelegy Ellipta patents expire, and when can generic versions of Trelegy Ellipta launch?
Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are nineteen patents protecting this drug.
This drug has four hundred and eighty-nine patent family members in fifty-one countries.
The generic ingredient in TRELEGY ELLIPTA is fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fluticasone furoate; umeclidinium bromide; vilanterol trifenatate profile page.
Summary for TRELEGY ELLIPTA
| International Patents: | 489 |
| US Patents: | 19 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRELEGY ELLIPTA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TRELEGY ELLIPTA |
| DailyMed Link: | TRELEGY ELLIPTA at DailyMed |
Generic Entry Opportunity Date for TRELEGY ELLIPTA
Generic Entry Date for TRELEGY ELLIPTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TRELEGY ELLIPTA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 4 |
Recent Litigation for TRELEGY ELLIPTA
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. | 2015-09-08 |
| GlaxoSmithKline Intellectual Property Management Limited v. Sandoz Inc. |
Synonyms for TRELEGY ELLIPTA
| FF/UMEC/VI |
| Fluticasone furoate mixture with umeclidinium and vilanterol |
| Fluticasone furoate, umeclidinium and vilanterol |
| S900007500 |
US Patents and Regulatory Information for TRELEGY ELLIPTA
International Patents for TRELEGY ELLIPTA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 177042 | Start Trial |
| Poland | 359999 | Start Trial |
| Israel | 191939 | Start Trial |
| Japan | 5107918 | Start Trial |
| United Kingdom | 0623405 | Start Trial |
| Germany | 60331891 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TRELEGY ELLIPTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1740177 | CA 2014 00052 | Denmark | Start Trial | PRODUCT NAME: UMECLIDINIUMBROMID; REG. NO/DATE: EU/1/14/922/001-003 20140428 |
| 1305329 | 300343 | Netherlands | Start Trial | 300343, 20210803, EXPIRES: 20230110 |
| 1425001 | CA 2014 00021 | Denmark | Start Trial | PRODUCT NAME: VILANTEROL ELLER ET SALT ELLER SOLVAT DERAF, HERUNDER VILANTEROL TRIFENATAT; REG. NO/DATE: EU/1/13/886/001-006 20131113 |
| 1425001 | 2014C/026 | Belgium | Start Trial | PRODUCT NAME: VILANTEROL TRIFENATATE; AUTHORISATION NUMBER AND DATE: EU/1/13/886/001 20131114 |
| 1305329 | 12/2008 | Austria | Start Trial | PRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE; REGISTRATION NO/DATE: EU/1/07/434/001 - EU/1/07/434/003 20080111 |
| 2506844 | C20180017 00244 | Estonia | Start Trial | PRODUCT NAME: FLUTIKASOONFUROAAT/UMEKLIDIINIUM/VILANTEROOL;REG NO/DATE: EU/1/17/1236 17.11.2017 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
